| WHITEHAWK THERAPEUTICS |
| USA |
| Gesundheit |
| US00032Q1040 / A3CSR9 |
| 3350 (Frankfurt) / WHWK (NASDAQ) |
| FRA:3350, ETR:3350, 3350:GR, NASDAQ:WHWK |
| - |
| https://ir.whitehawktx.co.. |
|
Whitehawk Therapeutics, Inc. is a clinical-stage oncology therapeutics company focused on developing antibody-drug conjugate (ADC) cancer treatments. Its current portfolio centers on three ADC assets designed to target clinically validated proteins a..
>Volltext.. |
| 162.22 Mio. EUR |
| -5.43 Mio. EUR |
| - |
| -77.25 Mio. EUR |
| -71.66 Mio. EUR |
| -1 EUR |
| - |
| 76.51 Mio. EUR |
| -62.25 Mio. EUR |
| 17.16 |
| -100% |
| -690.39% |
| - |
| - |
| - |
| - |
| WHITEHAWK THERAPEUTICS, WHITEHAWK THERAPEUTIC, AADI BIOSCIENCES |
| 09.11.26 |
|